Company intelligence / Profile preview
MyoPax
Berlin, Berlin, Germanymyopax.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
MyoPax has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for its lead regenerative cell therapy targeting Exstrophy-Epispadias Complex. The company’s proprietary approach uses patient-specific, highly regenerative muscle stem cells. The first-in-human MuST clinical trial for EEC repair began in Germany with academic sponsorship. Other pipeline assets remain preclinical.
- Therapeutic areas
- OtherRare DiseasesNeurology
- Modalities
- Stem cell therapyCRISPR/Cas9
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Bayer Co.Lab Berlin incubator residencyCharité Universitätsmedizin Berlin as academic sponsor of the MuST trialHospital Barmherzige Brüder St. Hedwig/University of Regensburg as a study site
Beyond the preview
Go deeper on MyoPax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MyoPax.